

22850



OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.

nt and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Dox 1450 Alexandria, Viginia 22313-1450 www.uspic.gov

APPLICATION NUMBER

1940 DUKE STREET

ALEXANDRIA, VA 22314

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/801,847

03/17/2004

Thomas Hermann

250350US OX DW

CONFIRMATION NO. 3961

FORMALITIES LETTER

\*OC000000012687041\*

Date Mailed: 05/17/2004

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

■ For Rules Interpretation, call (703) 308-4216

■ To Purchase Patentin Software, call (703) 306-2600

OBLON, SPIVAL MAIER & NEUSTADT, P.C. DOCKETING DEP

Replies should be mailed to:

Mail Stop Missing Parts

**Commissioner for Patents** 

Initials/Date Docketed: CAX 5 / 7 - 17 - 54

Type of Resp(s): Reg Seg Cst

Due Date(s): 7 - 17 - 54

#### P.O. Box 1450 Alexandria VA 22313-1450

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

DOCKET NO: 250350US0X DIV



#### IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

THOMAS HERMANN, ET AL. : ATTN: APPLICATION DIVISION

SERIAL NO: 10/801,847

FILED: MARCH 17, 2004

FOR: NUCLEOTIDE SEQUENCE

CODING FOR THE OTSA PROTEIN

### LETTER TO PTO IN RESPONSE TO THE OFFICE COMMUNICATION MAILED MAY 17, 2004

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicants note the following. A statement that the Sequence Listing filed in the present application is identical to the computer-readable Sequence Listing filed in Parent Application U.S. Serial No. 10/058,945 has already been made of record via the Preliminary Amendment filed with this application on March 17, 2004. In particular, Applicants direct the Office's attention to page 6 of that Preliminary Amendment (for reference a copy of the Preliminary Amendment is attached). Furthermore, a computer-readable Sequence Listing is not deemed to be necessary in the application as the Applicants have already requested in accordance with 37 C.F.R.§1.821(e) to use the last-filed computer-readable Sequence Listing filed in the parent application as a computer-readable Sequence

Listing for the present application. No further action is deemed necessary. Further examination on the merits is requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C. Norman F. Oblon

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 Daniel J. Pereira, Ph.D. Registration No. 45,518



ATTN: APPLICATION BRANCH

# OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT

## THIS IS A RESPONSE TO A NOTICE TO COMPLY

ATTORNEYS AT LAW

P.C.

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

Re: Inventor:

Thomas HERMANN, et al.

Serial No:

10/801,847

Filed:

March 17, 2004

For:

NUCLEOTIDE SEQUENCE CODING FOR THE OTSA PROTEIN

SIR:

Attached hereto for filing are the following papers:

Notice to Comply – Return Copy
Letter to PTO in Response to the Office Communication mailed May 17, 2004
Copy of Preliminary Amendment w/Sequence Listing (Paper) filed March 17, 2004

Our check in the amount of \$0.00 is attached covering any required fees. In the event that any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 CFR 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 CFR 1.136 for the necessary extension of time. A duplicate of this sheet is enclosed.

Respectfully Submitted,

250350US0X DIV

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Docket No.

Daniel J. Pereira, Ph.D. Registration No. 45,518